Radiotherapy Plus Concurrent or Sequential Temozolomide for Glioblastoma in the Elderly: A Meta-Analysis
Figure 3
The aggregate estimate for the incidence of patients who experienced at least one grade 3–4 hematological adverse event in combined RT/TMZ groups.